Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors
November 29 2018 - 04:35PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced the appointment of Adam Cutler to the Company’s board of
directors, effective December 1, 2018.
“We are pleased to welcome Mr. Cutler to Navidea’s board of
directors,” said Mr. Jed A. Latkin, Chief Executive Officer of
Navidea. “He will be a significant asset to the Company, as he has
over 20 years of experience in equity research, investor relations,
capital markets, business development, finance and management
consulting. His diverse perspective will help drive the Company
forward through an important part of our evolution.”
“I am excited to join Navidea’s board of directors and help the
Company advance the business and its novel imaging pipeline,”
commented Adam Cutler. “By applying the underlying technology from
the Manocept CD206 targeting platform, Navidea has the potential to
make a difference in the lives of patients by developing
next-generation diagnostic agents and targeted therapies for
autoimmune disorders, inflammatory diseases and an array of other
indications.”
Adam Cutler joined Molecular Templates, Inc. as its Chief
Financial Officer in November 2017. Prior, he was Senior Vice
President of Corporate Affairs for Arbutus Biopharma
Corporation, where he was responsible for investor relations and
contributed to the company’s business development and corporate
finance efforts from March 2015 to November 2017. From 2012 to
2015, he was a Managing Director for The Trout Group
LLC and Trout Capital LLC, where he executed financings
and advised public and private life science companies on investor
relations and capital raising strategies. From 2000 to 2012, Mr.
Cutler worked as a biotechnology equity research analyst with
Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of
America Securities. He also worked in healthcare consulting as an
Analyst at The Frankel Group and a Consultant
for Ernst & Young LLP. He currently serves on the Board of
Directors for Inmed Pharmaceuticals. He earned his Bachelor of
Arts degree in Economics from Brandeis University.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the
sites and pathways of disease and enable better diagnostic
accuracy, clinical decision-making, and targeted treatment.
Navidea’s Manocept platform is predicated on the ability to
specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the
molecular backbone of Tc99m tilmanocept, the first product
developed and commercialized by Navidea based on the platform. The
development activities of the Manocept immunotherapeutic platform
are being conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
products and advancing the Company’s pipeline through global
partnering and commercialization efforts.
For more information, please visit www.navidea.com.
Forward-Looking Statements
This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. We have based these forward-looking statements
largely on our current expectations and projections about future
events and financial trends affecting the financial condition of
our business. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including, among
other things: any future actions by Platinum-Montaur; general
economic and business conditions, both nationally and in our
markets; our history of losses and uncertainty of future
profitability; the final outcome of the CRG litigation in Texas and
Ohio; our ability to successfully complete research and further
development of our drug candidates; the timing, cost and
uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future
financial performance, financing plans and the impact of
competition; our ability to raise capital sufficient to fund our
development and commercialization programs; our ability to
implement our growth strategy; anticipated trends in our business;
advances in technologies; our ability to comply with the NYSE
American continued listing standards; and other risk factors
detailed in our most recent Annual Report on Form 10-K and other
SEC filings. You are urged to carefully review and consider the
disclosures found in our SEC filings, which are available
at www.sec.gov or at http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181129005790/en/
Navidea Biopharmaceuticals, Inc.Jed Latkin, CEO,
614-973-7490jlatkin@navidea.comorEdison AdvisorsJoseph Green,
646-653-7030jgreen@edisongroup.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2023 to Mar 2024